Afatinib (Afa) plus bevacizumab (Bev) combination after acquired resistance (AR) to EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC): Multicenter single arm phase II trial (ABC-study).

Authors

Akito Hata

Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Kobe, Japan

Akito Hata , Nobuyuki Katakami , Reiko Kaji , Toshihide Yokoyama , Toshihiko Kaneda , Motohiro Tamiya , Takako Inoue , Hiromi Kimura , Yukihiro Yano , Daisuke Tamura , Satoshi Morita , Shunichi Negoro

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Phase II trial of lazertinib in epidermal growth factor receptor (EGFR) mutation-positive (M+), metastatic non-small cell lung cancer (NSCLC) patients with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (TKI) (KCSG LU20-15).

First Author: Min Hee Hong

insert_chart_outlined

Poster

2023 ASCO Quality Care Symposium

bookmark_border

Stepwise prolongation of overall survival from first- to third-generation EGFR-tyrosine kinase inhibitors in non-small cell lung cancer and the prognostic impact of concomitant antacids.

First Author: Kiyoaki Uryu

insert_chart_outlined

Poster

2021 ASCO Quality Care Symposium

bookmark_border

Real-world treatment patterns of metastatic non-small cell lung cancer (mNSCLC) patients receiving epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).

First Author: Rahul Shenolikar

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).

First Author: Satoru Miura